The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
New Zealand introduced a tailor-made vaccine (MeNZB) for epidemic control of Group B meningococcal disease. The Intensives Vaccine Monitoring Programme (IVMP), which prospectively collected data electronically on a cohort of children receiving vaccinations in sentinel practices across NZ, was developed as part of a national multi-faceted safety strategy. The main aim of the IVMP was to identify the presence of unexpected adverse events occurring with MeNZB vaccination. We describe the methodology and success factors plus consider the limitations encountered in this system which shows potential as a means for post-marketing vaccine and medicine surveillance in the future.
Tatley
Michael V
MV
New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand. michael.tatley@otago.ac.nz
Kunac
Desireé L
DL
McNicholas
Anne
A
Zhou
Lifeng
L
Ballantyne
Suzie
S
Ashton
Janelle
J
Stehr-Green
Paul
P
Galloway
Yvonne
Y
Reid
Stewart
S
D016907:Adverse Drug Reaction Reporting Systems; D004582:Electronics, Medical; D006801:Humans; D007223:Infant; D022401:Meningococcal Vaccines / Q000009:adverse effects*; D009520:New Zealand; D011358:Product Surveillance, Postmarketing / Q000379:methods*
D022401:Meningococcal Vaccines